| Date | Title | Description |
| 16.03.2026 | Alto Neuroscience: $120 Million Raised To Advance Treatment-Resistant Depression Drug Candidate | Alto Neuroscience, a clinical-stage biopharmaceutical company developing precision medicines for neuropsychiatric disorders, announced it has secured approximately $120 million in a private placement financing.
The financing was led by Comm... |
| 11.11.2025 | NYSE Content Advisory: Pre-Market Update + Government Shutdown Nears End After 42 Days | NEW YORK, Nov. 11, 2025 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begins.
Kristen Sch... |
| 13.03.2025 | Christopher Nixon Cox Named Chairman of High-Trend International Group | SINGAPORE, March 13, 2025 /PRNewswire/ -- High-Trend International Group (NASDAQ: HTCO) (the "Company"), an international shipping company, today announced the appointment of Christopher Nixon Cox, as Chairman of the Company, effe... |
| 06.02.2024 | AI neurotech health company Elemind comes out of stealth with $12 million | The company has developed a wearable that can read individual brainwaves and respond in real-time
Right now, the best way to diagnose mental health conditions, such as depression and anxiety, is self-reported data from questionnaires like t... |
| 02.02.2024 | Brain drug developer Alto Neuroscience prices $129M IPO | - |
| 20.12.2023 | Fierce Biotech Fundraising Tracker '23: Carmot spinoff Kimia raises $55M; Lassen fuels for fibro-inflammatory mission | We've launched a new Fierce Biotech Fundraising Tracker for 2023 to track all the venture capital flowing into the industry.
While biotech VC investments in 2022 failed to live up to 2021's banner year, the second half still saw a steady st... |
| 21.11.2023 | Alto Neuroscience Closes $45M Series C Financing | Alto Neuroscience, a Los Altos, CA-based mental health company, raised $45M in Series C funding.
The round was led by InVivium Capital, with participation from additional new investors Franklin Templeton, Point72, Eli Lilly and Company, and... |
| 02.02.2023 | Depression treatments haven't changed much in decades. Here are the promising new drugs that could be more precise, work faster, and help more people. | Getty Images
Advances in depression treatment have been rare over the past few decades. But biotech companies are looking for ways to improve treatments. While some are developing drugs that work faster, others are targeting subtypes of the... |
| 31.01.2023 | AI drug developer Alto Neuroscience raises $25M and more digital health fundings | Photo: FG Trade/Getty Images |
| 30.01.2023 | 50 recently-funded startups to watch in 2023 | With the ongoing economic downturn and fear of a recession, tech startups have been hit hard as investors pulled back from new venture deals and reduce their investment in startups with exposure to recession. Further expounding on the fundi... |
| 30.01.2023 | Alto Neuroscience Inks $25M in Series B |
LOS ALTOS, CA, Alto Neuroscience Inc. today announced a $25 million equity investment by new investor, Alpha Wave Ventures.
>> Click here for more funding data on Alto Neuroscience
>> To export Alto Neuroscience funding data... |
| 30.01.2023 | Alto Neuroscience Raises $60M in Series B Financing | Alto Neuroscience, a Los Altos, CA-based company providing precision psychiatry by developing targeted medicines, raised an additional $25M in Series B funding, which now totals $60M.
New backer Alpha Wave Ventures made the investment. In a... |
| 23.01.2023 | Startups measuring the brain that you need to know | Companies are using biomarkers to diagnose and treat mental illness and other neurological disorders
Mental illness is considered the silent pandemic that's been overlooked since the start of COVID. The World Health Organization found the g... |
| 11.01.2023 | A scientist quit Stanford to chase a new way to treat depression. He just shared an early sign that his approach could work. | Dr. Amit Etkin is the founder and CEO of Alto Neuroscience. Alto Neuroscience
Alto Neuroscience is focused on developing precision medicine for mental health. On Tuesday, the company announced some promising signs for its treatment ALTO-100... |
| 10.01.2023 | Alto Neuroscience Announces Positive Results for ALTO-100 in Phase 2 Study Supporting Advancement of First-in-Class Mechanism for Treating Depression | Alto Neuroscience reported results from its Phase 2a study of ALTO-100, demonstrating clear evidence of efficacy and favorable safety in patients with MDD. In the study, patients with a biomarker profile that ties back to a mechanistic unde... |
| 08.12.2022 | Alto Neuroscience Presents New Data Leveraging EEG and Machine Learning to Predict Individual Response to Antidepressants at the 61st Annual Meeting of the American College of Neuropsychopharmacology | Alto Neuroscience announced a presentation of new data on the discovery and validation of a machine learning model for predicting individual response to antidepressant treatment at the 61st annual meeting of the American College of Neuropsy... |
| 15.11.2022 | Alto Neuroscience announced its emergence from stealth with $40 million in funding to advance the largest clinical-stage pipeline of precision psychiatry medicines. Similarly, in 2021 | - |
| 28.10.2022 | StartUPDATES: New developments from healthcare startups | Aptus Life, a virtual hub that connects patients and providers with RPM and CCM, will be transitioning its focus from diabetes to general healthcare. This change will make its platform in higher demand by giving more providers access to the... |
| 25.10.2022 | Alto Neuroscience Raises $35M Series B Financing | Alto Neuroscience, a Los Altos, CA-based neuro-tech company which specializes in precision psychiatry, raises $35M Series B Financing.
The round was led by Lightswitch Capital and Alkeon Capital, with participation from Sobrato Capital, Nov... |
| 25.10.2022 | Alto Neuroscience Closes $35M Series B Round |
LOS ALTOS, CA, Alto Neuroscience today announced the closing of a $35 million Series B financing.
>> Click here for more funding data on Alto Neuroscience
>> To export Alto Neuroscience funding data to PDF and Excel, click h... |
| 03.03.2022 | Report: Mental health startups raise $5.5B globally in 2021 | Photo: Halfpoint Images/Getty Images |
| 02.02.2022 | Mental health companies that raised funding in 2021 | Funding to mental health companies was $5.1 billion last year, nearly doubling from 2020
Mental health problems, especially in young people, have been on the rise for a while now: a CDC report found that, in 2019, more than 1 in 3 high scho... |
| 15.10.2021 | Ozy, Theranos, oh my. How startup culture is kind of like Instagram | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox.
I’ll go ahead and say it: Ozy and Theranos are not the same thing.
Paid Content How to ensure you... |
| 15.10.2021 | Alto Neuroscience Emerges with $32M Series A |
LOS ALTOS, CA, Alto Neuroscience, a mental health therapeutics startup, announced its emergence from stealth with $40 million in funding.
>> Click here for more funding data on Alto Neuroscience
>> To export Alto Neuroscienc... |
| 15.10.2021 | Ozy, Theranos, oh my. How startup culture is kind of like Instagram | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox.
I’ll go ahead and say it: Ozy and Theranos are not the same thing.
Paid Content How businesses ca... |
| 14.10.2021 | Alto Neuroscience Emerges with Largest Clinical-Stage Precision Psychiatry Pipeline and $40 Million in Financing | --Advancing 11 clinical-stage assets across psychiatric conditions with Phase 2 data readouts in MDD and PTSD for each of its three lead candidates expected by mid-2023--
--Over $40 million in capital raised, including a $32 million Series ... |
| 14.10.2021 | Alto Neuroscience Emerges with Largest Clinical-Stage Precision Psychiatry Pipeline and $40 Million in Financing | --Advancing 11 clinical-stage assets across psychiatric conditions with Phase 2 data readouts in MDD and PTSD for each of its three lead candidates expected by mid-2023--
--Over $40 million in capital raised, including a $32 million Series ... |
| 09.05.2021 | The human-focused startups of the hellfire | Disasters may not always be man-made, but they are always responded to by humans. There’s a whole panoply of skills and professions required today to respond to even the tiniest emergency, and that doesn’t even include the needs during pre-... |
| 26.04.2021 | With a third of its capital deployed, Risk & Return is transforming how we think about emergency response | Disasters are, unfortunately, a growth business, and the frontlines that were once distant have moved much closer to home. Wildfires, hurricanes, floods, tornadoes — let alone a pandemic — has forced much of the United States and increasing... |
| - | Alto Neuroscience | “Precision medicine for the brain is here. We are pioneering an approach to psychiatric drug development which matches the right patient with the right Alto drug based on AI-derived brain biomarkers.” |
| - | Startups are measuring your brain waves and analyzing your voice to figure out how to better treat mental-health disorders like depression | Getty Images This story is available exclusively to Insider subscribers. Become an Insider and start reading now.
Redeem now
Startups are measuring brain waves and the sound of your voice to better treat depression. The measurements, called... |
